Integra LifeSciences (NASDAQ:IART) Releases Q1 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its first quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.40 to $0.45 for the period, compared to the consensus earnings per share estimate of $0.54. The company issued revenue guidance of $375 million to $385 million, compared to the consensus revenue estimate of $400.11 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Citigroup upped their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Morgan Stanley began coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $21.45 on Tuesday. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $44.91. The firm has a market capitalization of $1.66 billion, a PE ratio of -236.16, a PEG ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock’s fifty day moving average is $23.68 and its 200 day moving average is $21.81.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same quarter last year, the firm earned $0.89 earnings per share. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.